IMRX saw its Momentum Indicator move below the 0 level on September 29, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator turned negative. In of the 43 cases, the stock moved further down in the following days. The odds of a decline are at .
IMRX moved below its 50-day moving average on August 24, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IMRX entered a downward trend on September 25, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Oscillator exited the oversold zone, of 16 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 28 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on September 26, 2023. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in of 17 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in of 118 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.991) is normal, around the industry mean (22.693). P/E Ratio (0.000) is within average values for comparable stocks, (131.605). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.099). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. IMRX's P/S Ratio (5000.000) is very high in comparison to the industry average of (304.777).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
A.I.dvisor tells us that IMRX and ORMP have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMRX and ORMP's prices will move in lockstep.